Navigation Links
FDA approves drug to treat Duchenne muscular dystrophy
Date:2/9/2017

SILVER SPRING, Md., Feb. 9, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

Corticosteroids are commonly used to treat DMD across the world. This is the first FDA approval of any corticosteroid to treat DMD and the first approval of deflazacort for any use in the United States.

"This is the first treatment approved for a wide range of patients with Duchenne muscular dystrophy," said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We hope that this treatment option will benefit many patients with DMD."

DMD is the most common type of muscular dystrophy. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. The first symptoms are usually seen between 3 and 5 years of age and worsen over time. The disease often occurs in people without a known family history of the condition and primarily affects boys, but in rare cases it can affect girls. DMD occurs in about one of every 3,600 male infants worldwide.

People with DMD progressively lose the ability to perform activities independently and often require use of a wheelchair by their early teens. As the disease progresses, life-threatening heart and respiratory conditions can occur. Patients typically succumb to the disease in their 20s or 30s; however, disease severity and life expectancy vary.

The effectiveness of deflazacort was shown in a clinical study of 196 male patients who were 5 to 15 years old at the beginning of the trial with documented mutation of the dystrophin gene and onset of weakness before age 5. At week 12, patients taking deflazacort had improvements in a clinical assessment of muscle strength across a number of muscles compared to those taking a placebo. An overall stability in average muscle strength was maintained through the end of study at week 52 in the deflazacort-treated patients. In another trial with 29 male patients that lasted 104 weeks, deflazacort demonstrated a numerical advantage over placebo on an assessment of average muscle strength. In addition, although not statistically controlled for multiple comparisons, patients on deflazacort appeared to lose the ability to walk later than those treated with placebo.

The side effects caused by Emflaza are similar to those experienced with other corticosteroids. The most common side effects include facial puffiness (Cushingoid appearance), weight gain, increased appetite, upper respiratory tract infection, cough, extraordinary daytime urinary frequency (pollakiuria), unwanted hair growth (hirsutism) and excessive fat around the stomach (central obesity).

Other side effects that are less common include problems with endocrine function, increased susceptibility to infection, elevation in blood pressure, risk of gastrointestinal perforation, serious skin rashes, behavioral and mood changes, decrease in the density of the bones and vision problems such as cataracts. Patients receiving immunosuppressive doses of corticosteroids should not be given live or live attenuated vaccines.

The FDA granted this application fast track designation and priority review. The drug also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The sponsor is receiving a rare pediatric disease priority review voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. A voucher can be redeemed by a sponsor at a later date to receive priority review of a subsequent marketing application for a different product. This is the ninth rare pediatric disease priority review voucher issued by the FDA since the program began.

Emflaza is marketed by Marathon Pharmaceuticals of Northbrook, Illinois.

Additional information:
FDA approved drugs: Questions and Answers 
Novel drug approvals for 2017

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov 
Consumer Inquiries: 888-INFO-FDA

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-approves-drug-to-treat-duchenne-muscular-dystrophy-300405176.html


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Federal judge approves consent decree with California dietary supplement distributor, Regeneca Worldwide
2. FDA approves Trulance for Chronic Idiopathic Constipation
3. FDA approves first drug for spinal muscular atrophy
4. FDA approves Eucrisa for eczema
5. Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug
6. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
7. FDA approves Intrarosa for postmenopausal women experiencing pain during sex
8. FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
9. FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheims STIOLTO RESPIMAT for COPD Health-Related Quality of Life
10. FDA approves Briviact to treat partial onset seizures
11. FDA Approves Takedas Dexilant SoluTab (dexlansoprazole)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2018)... ... ... Jin Y. Kim, a leading board-certified periodontist who has dedicated his career ... periodontal disease in Chino Hills, CA, to take advantage of LANAP®, the FDA-cleared ... solutions for the estimated 48 percent of people who have some form of gum ...
(Date:12/14/2018)... ... 14, 2018 , ... Becker's Healthcare and Becker's Hospital Review ... 10th Annual Meeting April 1 to 4, 2019, at the Hyatt Regency in ... full agenda of business-focused and strategic discussions on the healthcare industry and organizational ...
(Date:12/13/2018)... ... , ... The American Board of Pathology (ABPath) and the ... award Continuing Medical Education (CME/SAM) credits to participants in ABPath CertLink®, an innovative ... educational provider for pathologists, as the accredited ACCME provider. ASCP will enter into ...
Breaking Medicine Technology:
(Date:12/13/2018)... ... December 13, 2018 , ... Evergreen Healthcare Partners is ... brings over 20 years of leadership experience in healthcare technology, consulting, project management ... strong teams and creating vibrant cultures of personal growth and development. In her ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... Careers at High Schools , As part of its commitment to providing more jobs ... schools , Fellow Health Partners, Inc., a New York based medical business solutions ...
(Date:12/13/2018)... ... , ... Mediaplanet today announces the launch of this December’s issue of “Transplants: ... encouraging readers to sign up as an organ and/or whole-body donor for the 120,000 ... , One organ donor can save up to 8 lives, however, an average of ...
(Date:12/13/2018)... ... December 13, 2018 , ... The ... Bureau for presentations at hospital grand rounds, medical schools, medical conferences and other ... professionals the evidence-based training in Lifestyle Medicine—using lifestyle prescriptions as a therapeutic intervention ...
(Date:12/10/2018)... , ... December 10, 2018 , ... In the aftermath ... situation has more recently been reinforced by the Me Too movement. To redress the ... set their inner Man free and become the Men they were always meant to ...
Breaking Medicine News(10 mins):